MedTrace Logo

Substance Misuse To Psychosis for Stimulants

NCT03485417 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2026-03-27

No results posted yet for this study

Summary

In Hong Kong, less than 5% of stimulants abusers were reported to misuse these substances via injection. Also, it is well known that patients with co-morbid substance abuse/dependence and psychosis or schizophrenia-related disorders are prone to earlier treatment discontinuation and high oral medication non-adherence, resulting in poorer overall outcomes. With the recent availabilities of the 4-weekly long-acting injectable form of aripiprazole, and the 4-weekly and the 3-monthly long-acting injectable form of paliperidone palmitate, on the background of the surging phenomenon of stimulant misuses in Hong Kong, it is a timely opportunity to conduct an early pharmacotherapy intervention study to offer an evidence-based strategy aiming to stop individuals with substance use disorders with psychosis to develop into a more chronic disabling dependence or co-morbid state.

Conditions

  • Stimulant Use With Stimulant-Induced Psychotic Disorder (Diagnosis)
  • Schizophrenia and Related Disorders
  • Stimulant Dependence
  • Stimulant Abuse
  • Pharmacotherapy

Interventions

DRUG

Aripiprazole

for oral or depot preparation

DRUG

Paliperidone

for oral or depot

OTHER

Treatment as Usual

to be decided by treating psychiatrist with Rx other than aripiprazole or paliperidone

Sponsors & Collaborators

  • Queen Mary Hospital, Hong Kong

    collaborator OTHER

  • North District Hospital

    collaborator OTHER

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • albert KK Chung, Dr · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-01
Primary Completion
2024-05-31
Completion
2025-05-31
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03485417 on ClinicalTrials.gov